High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16/CA125 mutations

Immunotherapies have dramatically improved survival outcome for patients with melanoma. MUC16 encodes cancer antigen 125 (CA125), which is frequently mutated in melanoma. In this study, we correlated the MUC16 mutational status with the following: tumor mutation burden (TML), multiple immune-related...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qinghua, Yang, Yichen, Yang, Meng, Li, Xiangchun, Chen, Kexin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346065/
https://www.ncbi.nlm.nih.gov/pubmed/32491995
http://dx.doi.org/10.18632/aging.103296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346065/
https://www.ncbi.nlm.nih.gov/pubmed/32491995
http://dx.doi.org/10.18632/aging.103296

Ejemplares similares